Computational Design and Screening
Selected MyD88-targeted mimetic peptide candidates are validated through screening to improve cell penetration and stability, followed by adjustments to optimize their activity in blocking MyD88-mediated signaling.
Solutions
Online Inquiry
Mimetic Peptides Development
The MyD88 signaling pathway plays an important role in the pathogenesis of several diseases such as inflammatory, autoimmune, infectious, and cancerous diseases. Monoclonal antibodies are one type of therapeutic agent that has a vigorous effect in disease management. Protheragen is a one stop research service provider for the development of monoclonal antibodies targeting MyD88.
Introduction to MyD88-Targeted Mimetic Peptides
MyD88-targeted mimetic peptides are designed to mimic the key functional domains of MyD88, enabling the modulation of its signaling pathways. These peptides can bind to specific receptors or downstream signaling molecules, effectively disrupting MyD88-mediated immune responses. The development of such peptides offers potential therapeutic applications for treating inflammatory diseases, autoimmune disorders, and certain cancers. Their high specificity and ability to regulate MyD88 signaling make them promising candidates for targeted therapies.
Fig.1 MyD88 is associated with immune escape. (Song, J., et al., 2024)Design Strategy and Key Domains
In design strategies and key domains targeting MyD88 network mimetic peptides and MyD88 interaction, two strategies come into play: TIR domain and BB-loop. It enables the MyD88 homodimerization and assists in the transduction of the downstream signals. The intention is to develop peptides inhibitors which can act as drugs that easily break protein interactions.
Peptide Optimization and Modification
MyD88-targeting mimetic peptides having therapeutic functions are being actively modified to impact different processes. TIR domain-derived peptides interact with MyD88-TLR complexes while BB-loop mimetics suppress the MyD88-TIR dimerization. Novel cell penetrating peptide conjugates show enhanced uptake and targeted delivery to immune cells. Given the flexible structure of the peptides, modifications can be done to increase their effectiveness in mechanobiology.
Structure-Based Design Approach
Rather effective MyD88-targeting peptides are designed bearing in mind some molecular biological factors, especially those perspectives that concern the interface of the BB-loop and TIR domain. The structure based approach uses molecular dynamics simulations to optimize the peptide sequences. Other optimization strategies include use of unnatural amino acids, high affinity binding strategies and improved internalization and distribution of peptides to tissues.
Our Services
Protheragen exclusive incorporates the MyD88-targeting mimetic peptide design with optimizing techniques. Subsequently are profiled and evaluated rationally to evaluate and treat these novel peptides. Moreover, peptides are powered with advanced tools to cater for parametric design and modeling to achieve optimal structure.
Workflow of MyD88-Targeted Mimetic Peptides Development
Peptide Synthesis and Optimization
Protheragen utilizes advanced computational tools to design peptide sequences targeting critical MyD88 domains, predicting their binding affinity and effectiveness through molecular simulations and virtual screening.
Preclinical Evaluation
Promising MyD88-targeted peptides undergo in vitro and in vivo evaluation, assessing pharmacokinetics (PK), pharmacodynamics (PD), safety, and target engagement to ensure efficacy in blocking MyD88 signaling.
Investigator-Initiated Trials (IITs)
Protheragen's IIT services accelerate the clinical testing of MyD88-targeted peptides, supporting protocol development, regulatory compliance, and trial management.
Types of MyD88-Targeted Diseases
- Autoimmune Diseases
- Inflammatory Diseases
- Transplant Rejection
- Ischemia-Reperfusion
- Allergic Diseases
- Cancers
- Neurodegenerative
- Metabolic Diseases
Protheragen adopts a rapid approach in the treatment of MyD88 related diseases offering a wide range of services which include peptide therapeutic development, disease model development, pharmacokinetics and drug safety evaluation. We also focus on the initiation of investigator-sponsored trials enabling us to fast-track the preliminary testing process and facilitate the development of new therapies.
If you are interested in our services, please don't hesitate to contact us.
Reference
- Song, J., et al. "Myd88 and Its Inhibitors in Cancer: Prospects and Challenges." Biomolecules 14.5 (2024).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.